in

Debiopharm and Ubix join forces to develop new anti-cancer modality

Debiopharm is a Switzerland-based biopharmaceutical company dedicated to developing and manufacturing therapies and drug delivery platforms for high unmet medical needs in oncology and infectious diseases.

The company identifies high-potential compounds and technologies, demonstrates their safety and efficacy in clinical trials, then selects large pharma commercialisation partners to deliver the products to patients worldwide.

This week, Debiopharm announced it had joined forces with South Korean Ubix Therapeutics on a new research project using both companies’ proprietary technologies. The two companies are aiming to develop a new drug modality known as Antibody Degraducer Conjugates (ADCs), by combining one of Ubix’s Degraducer molecules with Debiopharm’s antibody drug conjugate linker Multilink.

ADCs are highly targeted therapies that combine monoclonal antibodies with the cancer-killing drugs, designed to attack cancer cells while avoiding healthy cells. Linkers are crucial to the function of ADCs, helping to attach the cytotoxic payload to the antibody, stabilise the molecule during circulation and release the toxic payload specifically into the target tissue.

Debiopharm’s Multilink is a new cleavable linker platform that allows the loading of multiple drug payloads on an antibody, while Ubix’s Degraducer is a powerful, bifunctional, inhibitor technology that enables selective protein degradation and prolonged therapeutic effects. The companies hope the combined technologies will improve drug targeting and have a synergistic effect on tumour cells, resulting in the improved efficacy and safety of cancer therapies.

Ubix CEO BK Seo said of the partnership: “We are excited to explore Antibody Degraducer Conjugates with Debiopharm. In particular, we are pleased to take the opportunity to combine our Degraducer technology, having superior efficacy and high selectivity, with Debiopharm’s Multilink technology, having lots of advantages especially excellent potency through multiple loading capability.

“We believe that this collaboration will open up new opportunities to develop advanced cancer therapy.”

Reference